Eye Findings on Vigabatrin and Taurine Treatment in Two Patients with Succinic Semialdehyde Dehydrogenase Deficiency

Abstract

We describe for the first time two patients with succinic semialdehyde dehydrogenase (SSADH) deficiency, who were found to have abnormal electroretinogram (ERG) examinations at baseline, or 6 months after vigabatrin treatment was started. This was somewhat reversible with L-taurine treatment, or minimally progressive. The mechanism of injury to the retina may be induced by elevations of γ-aminobutyric acid causing peripheral photoreceptor and ganglion cell damage, and this can be exacerbated by the use of vigabatrin. The use of taurine supplementation in tandem with vigabatrin may allow reversal of retinopathy and mitigate or slow down further deterioration. Further prospective clinical trials are required to evaluate this further. We recommend starting L-taurine therapy together with vigabatrin if a trial of vigabatrin is commenced in a patient with SSADH deficiency. Close monitoring of visual fields or ERG is also recommended at baseline and during vigabatrin therapy.

Keywords

SSADH - vigabatrin toxicity - retinopathy - taurine - neuroprotection

• References

• 1 Pearl PL, Dorsey AM, Barrios ES, Gibson KM, Succinic semialdehyde dehydrogenase deficiency. In: Pagon RA, Adam MP, Ardinger HH. , et al, eds. GeneReviews [Internet] University of Washington, Seattle; 1993-2016
• 2 Gibson KM, Christensen E, Jakobs C , et al. The clinical phenotype of succinic semialdehyde dehydrogenase deficiency (4-hydroxybutyric aciduria): case reports of 23 new patients. Pediatrics 1997; 99 (4) 567-574
• 3 Jammoul F, Wang Q, Nabbout R , et al. Taurine deficiency is a cause of vigabatrin-induced retinal phototoxicity. Ann Neurol 2009; 65 (1) 98-107
• 4 Gropman A. Vigabatrin and newer interventions in succinic semialdehyde dehydrogenase deficiency. Ann Neurol 2003; 54 (Suppl. 06) S66-S72
• 5 Sergott W, Wheeles J, Szabo G, Smith M , et al. review of recommendations for visual function testing in patients treated with vigabatrin. Neuroophthalmology 2010; 34: 20-35
• 6 Frisén L, Malmgren K. Characterization of vigabatrin-associated optic atrophy. Acta Ophthalmol Scand 2003; 81 (5) 466-473
• 7 Wild JM, Hope-Ross M, Harding GFA , et al. Vigabatrin retinopathy. IOVS 2002; 43: 238
• 8 Hardus P, Verduin WM, Postma G, Stilma JS, Berendschot TT, van Veelen CW. Long term changes in the visual fields of patients with temporal lobe epilepsy using vigabatrin. Br J Ophthalmol 2000; 84 (7) 788-790
• 9 Duboc A, Hanoteau N, Simonutti M , et al. Vigabatrin, the GABA-transaminase inhibitor, damages cone photoreceptors in rats. Ann Neurol 2004; 55 (5) 695-705
• 10 Szabo , et al. In: Proceedings of the 32nd Meeting of the Society for Neuroscience; November 2–7, 2002; Orlando, FL
• 11 Jammoul F, Dégardin J, Pain D , et al. Taurine deficiency damages photoreceptors and retinal ganglion cells in vigabatrin-treated neonatal rats. Mol Cell Neurosci 2010; 43 (4) 414-421